---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268816"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:31:35.894910+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Intellia reports new Phase 1 data for NTLA-2001: median TTR reduction 91%, 55mg dose selected for Phase 3

## Summary
- Median serum TTR reduction of 91% and median residual TTR of 17 µg/mL at day 28 across 62 patients (doses ≥0.3 mg/kg).
- 29 patients with ≥12 months follow-up show sustained TTR reduction; no loss of activity over time.
- NTLA-2001 generally well tolerated; infusion-related reactions in 38% (mostly Grade 1-2); no dose-limiting toxicities.
- 55 mg fixed dose selected for global pivotal Phase 3 trial, expected to begin by year-end 2023; FDA IND clearance received.

## SEC filing metadata
- accession: 0001193125-23-268816
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/0001193125-23-268816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523268816/d536006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268816
- JSON: https://secwatch.observer/filing/0001193125-23-268816.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.